Insmed’s (INSM) Overweight Rating Reaffirmed at JPMorgan Chase & Co.
JPMorgan Chase & Co. reaffirmed their overweight rating on shares of Insmed (NASDAQ:INSM – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company’s stock. Several other equities analysts also recently issued reports on INSM. Evercore ISI upped their price […]
More Stories
TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Up 474.1% in December
TC Biopharm (Holdings) Plc (NASDAQ:TCBP – Get Free Report) was the target of a large growth in short interest in...
Invesco ESG NASDAQ Next Gen 100 ETF (NASDAQ:QQJG) Short Interest Up 500.0% in December
Invesco ESG NASDAQ Next Gen 100 ETF (NASDAQ:QQJG – Get Free Report) was the recipient of a significant increase in...
ITV (OTCMKTS:ITVPF) Shares Down 17.5% – Time to Sell?
ITV plc (OTCMKTS:ITVPF – Get Free Report)’s share price fell 17.5% during mid-day trading on Monday . The stock traded...
**Greenbrier Companies Inc. Shareholders Approve Directors and Compensation Plans at Annual Meeting**At the recent Annual Meeting of Shareholders held virtually on January 9, 2025, The Greenbrier Companies, Inc. (NYSE: GBX) saw significant proposals
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For...
NuVista Energy Ltd. (OTCMKTS:NUVSF) Sees Large Decline in Short Interest
NuVista Energy Ltd. (OTCMKTS:NUVSF – Get Free Report) saw a large drop in short interest in the month of December....
Short Interest in Nabtesco Co. (OTCMKTS:NCTKY) Decreases By 68.8%
Nabtesco Co. (OTCMKTS:NCTKY – Get Free Report) saw a significant decline in short interest in the month of December. As...